Latest news for DNB Bank (OTC:DNBBF) Stock

DNB Bank ASA is a Norwegian financial services group. About one fourth of its income derives from its international business, including other parts of Europe, Asia, and the Americas. The group offers a full range of financial services, including loans, savings, advisory services, insurance, and pension products for retail and corporate customers. Just under half of its credit exposure is to personal customers, overwhelmingly in residential mortgages. The other portion of its credit exposure is to large corporations, diversified across an array of industries, most notably oil and gas, shipping, and commercial real estate. The group's strategy emphasizes cost efficiency and customer service.

DNB Bank ASA

News

JBLU

JetBlue Signs Agreement With World Fuel Services To Supply Blended Sustainable Aviation Fuel At JFK Airport Starting Q4 2024; Initial 12-Month Deal Includes Minimum 1M Gallons Of Neat SAF With Option For Up To 4M Additional Gallons; JetBlue Invites New York Businesses To Help Scale SAF Market

Baird analyst David Rodgers maintains Highwoods Props (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIW#NYSE">HIW</a>) with a Neutral and raises the price target from $27 to $30.

Price Target

Analyst Ratings

Baird Maintains Neutral on Highwoods Props, Raises Price Target to $30

HC Wainwright &amp; Co. analyst Patrick Trucchio reiterates Compass Pathways (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPS#NASDAQ">CMPS</a>) with a Buy and maintains $120 price target.

Reiteration

CMPS

HC Wainwright & Co. Reiterates Buy on Compass Pathways, Maintains $120 Price Target

Boeing Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) reported <a target="_blank" href="https://www.benzinga.com/pressreleases/24/07/n40064718/boeing-reports-second-quarter-results" rel="noreferrer noopener">second-quarter 2024 results</a> and named Kelly Ortberg its new President and CEO, effective August 8, 2024.
Boeing reported a second-quarter revenue decline of 15% year-over-year to $16.866 billion, missing the consensus of $17.23 billion.
Adjusted loss per share expanded to $(2.90) from $(0.93) in the same quarter of 2024, missing the consensus of $(1.91).
The company stated that the results primarily reflect lower commercial delivery volume and losses on fixed-price defense development programs.
Boeing recorded an adjusted operating loss of $(1.392) billion for the quarter, compared to $(390) million a year ago. The core operating loss margin was (8.3)%.
Commercial Airplanes revenue fell 32% YoY to $6.003 billion, reflecting lower deliveries and planned higher period costs, including research and development.
Deliveries declined by 32%, and 92 airplanes were delivered, and the backlog included over 5,400 airplanes valued at $437 billion.
The 737 program gradually increased production during the quarter and still plans to increase production to 38 per month by year end.
Defense, Space &amp; Security revenue fell 3% year over year to $6.021 billion. The backlog was $59 billion, of which 31% represents orders from customers outside the U.S.
Global Services revenue grew by 3% YoY to $4.889 billion. The operating margin contracted 20 bps to 17.8%, reflecting higher commercial volume and mix.
Operating cash outflow for the six months ended June 30 totaled $(7.285) billion, compared to cash provided of $2.557 billion YoY; free cash outflow was $(4.3) billion.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="&#x1f534;WATCH LIVE: Boeing Q2 2024 Earnings Call &#x7C; $BA" width="500" height="281" src="https://www.youtube.com/embed/mraW07D-qZw?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Debt was $57.9 billion, up from $47.9 billion at the beginning of the quarter due to the issuance of new debt.
At the end of the quarter, cash and investments in marketable securities totaled $12.6 billion, and the total company backlog was $515.874 billion.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/equities/24/07/39928770/boeing-resumes-737-max-deliveries-to-china-after-regulatory-delay-report" rel="noreferrer noopener">Boeing Resumes 737 MAX Deliveries To China After Regulatory Delay: Report</a>
Additionally, Boeing announced Robert K. &#8220;Kelly&#8221; Ortberg as the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/07/n40064789/boeing-board-names-kelly-ortberg-president-and-ceo" rel="noreferrer noopener">company&#8217;s new president and chief executive officer</a>, effective August 8, 2024. Ortberg will also serve on Boeing&#8217;s Board of Directors.
Ortberg, 64, has over 35 years of aerospace experience. He began at Texas Instruments in 1983, joined Rockwell Collins in 1987, and became CEO in 2013.
He led its integration with United Technologies and RTX until 2021. He serves on the boards of RTX and Aptiv PLC and is a former Chair of the Aerospace Industries Association.
Price Action: BA shares are trading higher by 2.06% at $190.70 premarket at the last check on Wednesday.
Photo via Shutterstock

Earnings

Management

Tech

Boeing's Q2 Earnings: Huge Revenue Decline, Lower Deliveries, Names Former Aerospace Industries Association Chair Kelly Ortberg As New CEO

Baird analyst Michael Halloran maintains Hayward Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAYW#NYSE">HAYW</a>) with a Neutral and raises the price target from $16 to $19.

HAYW

Baird Maintains Neutral on Hayward Holdings, Raises Price Target to $19

Macro Economic Events

Econ #s

Economics

USA ADP Nonfarm Employment Change For July 122K Vs 147K Est.; 155K Prior

Baird analyst Ghansham Panjabi maintains Graphic Packaging Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPK#NYSE">GPK</a>) with a Outperform and raises the price target from $30 to $36.

Baird Maintains Outperform on Graphic Packaging Holding, Raises Price Target to $36

Macro Notification

General

ADP Nonfarm Employment Change (Jul) +122K vs +147K Est.

Fibromyalgia is a "diagnosable condition" in people suffering from Long COVID according to NASEM1 &nbsp;
Diagnosing fibromyalgia in Long COVID patients is expected to expand the potential addressable market for Tonmya relative to pre-COVID-19 pandemic estimates2
Tonmya is a potential new first-line non-opioid analgesic under development for the management of fibromyalgia with Fast Track designation: NDA submission target is second half of 2024, with potential for FDA approval in 2025
CHATHAM, N.J., July 31, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today provided an update on the potential impact on the size of the fibromyalgia market for its development candidate Tonmya (TNX-102 SL or cyclobenzaprine HCl sublingual tablets), based on the new definition of Long COVID by the U.S. National Academies of Sciences, Engineering and Medicine (NASEM) announced on June 11, 20241.

Biotech

TNXP

Tonix Pharmaceuticals Announces Potential Impact Of The U.S. National Academies New Definition Of Long COVID On The Size Of The Fibromyalgia Market For Tonmya

Baird analyst Michael Halloran maintains Flowserve (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLS#NYSE">FLS</a>) with a Neutral and raises the price target from $57 to $60.

Baird Maintains Neutral on Flowserve, Raises Price Target to $60

MNDY

Monday.com Announces Full Release Of Portfolio Management Solution; New Capabilities Enhance Strategic Initiative Management, Streamline Operations, And Boost Productivity Across Teams And Departments

In a recent development, chip ETFs have experienced a significant upswing as a result of President Biden&#8217;s decision to exempt some allies from the new rule governing chip exports to China.
This movement also comes on the heels of&nbsp;Advanced Micro Devices, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) <a href="https://www.benzinga.com/news/earnings/24/07/40060832/amd-skyrockets-over-9-lifting-along-with-ai-rival-nvidia-whats-going-on">posting its second-quarter</a> results which exceeded expectations and guided the current quarter's revenue above consensus. 
What Happened: According to <a href="https://pro.benzinga.com">Benzinga Pro</a>, on Wednesday, the GraniteShares 2x Long NVDA Daily ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDL#NASDAQ">NVDL</a>), which has 100% exposure to AMD&#8217;s peer Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) saw an 11.78% increase, trading at $52.65, up from Tuesday&#8217;s close of $47.10. 
The Direxion Daily Semiconductor Bull 3X Shares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOXL#NYSE">SOXL</a>) also experienced a significant boost, trading 10.71% higher at $41.23, compared to its previous close at $37.24.
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/07/40038854/why-bitcoin-etf-gbtc-is-down-a-whopping-10-today?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Why Bitcoin ETF GBTC Is Down A Whopping 11% Today</a>
ProShares Ultra Semiconductors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USD#NYSE">USD</a>) followed suit, with an 8.73% increase, trading at $110.98, a significant rise from Tuesday&#8217;s close at $102.07. The VanEck Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMH#NASDAQ">SMH</a>) saw a 4.20% increase, trading at $239.10, up from $229.47. Lastly, the iShares Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOXX#NASDAQ">SOXX</a>) rose by 3.69%, trading at $228.73, up from $220.58 on Tuesday.
Why It Matters: The Biden administration announced <a href="https://www.benzinga.com/24/07/40061267/asml-shares-surge-over-7-as-team-biden-plans-to-exempt-allies-from-new-rule-on-foreign-chip-equipmen">the new rule </a>on foreign chip equipment exports to China which will enhance U.S. authority to halt exports of semiconductor manufacturing equipment from certain foreign countries to Chinese chipmakers. However, shipments from key allies such as Japan, the Netherlands, and South Korea will be exempted, thereby limiting the rule's impact.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/07/40029681/trump-accuses-opec-of-manipulating-oil-prices-to-favor-kamala-harris-warns-she-will-be-a-disaste?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Trump Accuses OPEC Of Manipulating Oil Prices To Favor Kamala Harris, Warns &#8216;She Will Be A Disaster For The USA!&#8217;</a></li>
</ul>
Picture by blickpixel on Pixabay and Karolina Grabowska on Pexels and Osman Bugra Nuvasil on Shutterstock
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/topic/Pooja-Rajkumari" target="_blank" rel="noreferrer noopener">Pooja Rajkumari</a>

Sector ETFs

Pre-Market Outlook

ETFs

NVDA

NVDL

SOXL

iShares PHLX SOX Semiconductor Sector Index Fund

SOXX

NVDL, SOXL, And Other Chip-Stocks Tracking ETFs Are Trading Higher In Premarket Today: Here's Why

IMUNON, Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/IMNN#NASDAQ">IMNN</a>), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, today announced that it has entered into definitive securities purchase agreements for a registered direct offering of its common stock priced at-the-market under Nasdaq rules. In a concurrent private placement and also pursuant to the securities purchase agreements, the Company has agreed to issue to the investors unregistered warrants to purchase shares of common stock. Upon the closing of the offering, which is anticipated to occur on or about August 1, 2024, the Company expects to receive gross proceeds of $10 million, before deducting placement agent fees and other offering expenses payable by the Company. The closing of the offering is subject to customary closing conditions. &nbsp;
H.C. Wainwright &amp; Co. is acting as the lead placement agent for the offering. Brookline Capital Markets, a division of Arcadia Securities, LLC, is acting as co-placement agent.
Pursuant to the terms of the securities purchase agreements, the Company is selling an aggregate of 5,000,000 registered shares of its common stock, together with unregistered warrants to purchase up to 5,000,000 shares of its common stock, at a purchase price of $2.00 per share and accompanying warrant. The warrants will have an exercise price of $2.00 per share and will be exercisable immediately for a term of five and one-half years following the date of issuance.
The Company intends to use the net proceeds from the financing for working capital and general corporate purposes.

Offerings

IMNN

IMUNON Announces $10M Registered Direct Offering Of 5M Shares Of Common Stock, With Unregistered Warrants At A Price Of $2/Unit

CUTR

Cutera Announces Partnership With L'Oréal Japan To Exclusively Promote, Market, Sell And Distribute SkinCeuticals To Clinics In Japan

Baird analyst Andrew Wittmann maintains Ecolab (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ECL#NYSE">ECL</a>) with a Neutral and raises the price target from $243 to $267.

Baird Maintains Neutral on Ecolab, Raises Price Target to $267

Baird analyst Colin Sebastian maintains Electronic Arts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EA#NASDAQ">EA</a>) with a Outperform and raises the price target from $150 to $170.

Baird Maintains Outperform on Electronic Arts, Raises Price Target to $170

<a href="https://www.globenewswire.com/Tracker?data=a_q-8AU2_h2d1FBiU8IwPWsK-JlG3QyNTT6cAumZpPCOejpPS3otGFjKQBKJVJKv2K3feIyU2eMrmTzJYJmuf0q1PehJnsop39XoPtsFURs=">Graphjet Technology</a> ("Graphjet" or "the Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTI#NASDAQ">GTI</a>), a leading developer of patented technologies to produce graphite and graphene directly from agricultural waste, today announced that it has received formal notice from the Nasdaq Stock Market ("Nasdaq") stating that it is now in compliance with all applicable listing standards.

Graphjet Technology Regains Compliance with Nasdaq

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.alzamend.com%2F&amp;esheet=54102274&amp;newsitemid=20240731640799&amp;lan=en-US&amp;anchor=Alzamend+Neuro%2C+Inc.&amp;index=1&amp;md5=df568cbae4ffa1c27f23574fb9d3ac8f">Alzamend Neuro, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALZN#NASDAQ">ALZN</a>) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder ("BD"), major depressive disorder ("MDD") and post-traumatic stress disorder ("PTSD"), today announced that it has received a notification letter (the "Compliance Notice") from the Listing Qualifications Staff of the Nasdaq Stock Market, LLC ("Nasdaq") dated July 30, 2024, informing Alzamend that it has regained compliance with Nasdaq Listing Rule 5550(a)(2) (the "Minimum Bid Price Requirement"). In order to regain compliance with the Minimum Bid Price Requirement, Alzamend's common stock was required to maintain a closing bid price of at least $1.00 per share for a minimum of ten consecutive trading days. The Minimum Bid Price Requirement was met on July 29, 2024. Accordingly, in the Compliance Notice, Nasdaq stated that the matter is now closed.

ALZN

Alzamend Neuro Regains Compliance With Nasdaq's Minimum Bid Price Requirement

Baird analyst Peter Arment maintains Leonardo DRS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRS#NASDAQ">DRS</a>) with a Outperform and raises the price target from $26 to $30.

Baird Maintains Outperform on Leonardo DRS, Raises Price Target to $30

HC Wainwright &amp; Co. analyst Patrick Trucchio reiterates Voyager Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VYGR#NASDAQ">VYGR</a>) with a Buy and maintains $30 price target.

VYGR

HC Wainwright & Co. Reiterates Buy on Voyager Therapeutics, Maintains $30 Price Target

These Financial Services stocks are trading higher:-Heritage Financial Corp (HFWA) stock is trading at $17.76, a gain of $1.45, or 8.89%, on low volume.  Heritage Financial gets a Sentiment Score of Bearish from InvestorsObserver and receives an average analyst recommendation of Strong Buy with a price target of $20.80.  -

The Only Monthly Membership With a Positive ROI!

-

-

-

-

-

-

-

The Only Monthly Membership With a Positive ROI!

-

-

-

-

-

-

-

Comments

DNB Bank

News

Latest news for DNB Bank (OTC:DNBBF) Stock